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Objectives
To characterize the in vitro pharmacological properties
of AA71, a human monoclonal antibody against the
CGRP receptor.
Introduction
Calcitonin gene-related peptide (CGRP) is a neuropeptide
that plays a key role in the pathophysiology of migraine.
Clinical studies have demonstrated that CGRP receptor
antagonism is an effective approach in treating acute
migraine pain. We have previously reported the successful
generation of a group of human monoclonal antibodies
(MAb) that specifically target the human CGRP receptor
(1). In our present study, we detail the characterization of
AA71, a potent and selective human monoclonal antibody
against the CGRP receptor.
Results
AA71 potently competed with the binding of [125I]-CGRP
to the human CGRP receptor with a Ki of 0.03 nM. AA71
fully inhibited CGRP-stimulated cAMP production with
an IC50 of 2 nM in cell-based functional assays, with no
intrinsic agonist activity up to 10 ƒÝM. Functional potency
of AA71 at the cyno CGRP receptor was similar to that at
the human receptor with an IC50 of 4.5 nM, but potency
at dog, rabbit and rat receptors was significantly reduced
(>5000-fold). AA71 also demonstrated > 5000-fold selec-
tivity over other closely related receptors in the family.
Through a saturation analysis using SK-N-MC membrane
preparations, [125I]-AA71 was shown to bind the CGRP
receptor in a monophasic and saturable fashion with a Kd
of 0.08 nM. The binding of 0.1 nM [125I]-AA71 to
the CGRP receptor reached equilibrium at approximately
240 min. A prolonged dissociation of [125I]-AA71 binding
from the CGRP receptor was observed with a dissociation
t1/2 off of 267 min. In a competition study, CGRP¡¦s
capability of displacing [125I]-AA71 binding is signifi-
cantly less robust, with an observed Ki of 370 nM.
Conclusion
AA71 is a potent and selective antibody against the
human CGRP receptor with potential for use in the
treatment of migraine pain.
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